ACRS — Aclaris Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $85.82m
- -$33.29m
- $31.25m
Annual income statement for Aclaris Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.23 | 6.48 | 6.76 | 29.8 | 31.2 |
| Cost of Revenue | |||||
| Gross Profit | 0.172 | 1.35 | 2.05 | 17.8 | 13.2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 115 | 57.4 | 96.5 | 120 | 129 |
| Operating Profit | -111 | -50.9 | -89.7 | -89.9 | -97.4 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -114 | -51.3 | -90.9 | -86.9 | -88.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -114 | -51.2 | -90.9 | -86.9 | -88.5 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -161 | -51 | -90.9 | -86.9 | -88.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -161 | -51 | -90.9 | -86.9 | -88.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.3 | -1.2 | -1.6 | -1.33 | -1.19 |